1 / 51

最大限度地展示您的研究成果 英语医学论文写作实例分析 张科宏博士 常青藤编辑总裁 同济大学兼职教授 哈佛大学医学院助理教授( 2003 - 2007 ) Tel: 021-51370992

www.ivy-editing.com. 最大限度地展示您的研究成果 英语医学论文写作实例分析 张科宏博士 常青藤编辑总裁 同济大学兼职教授 哈佛大学医学院助理教授( 2003 - 2007 ) Tel: 021-51370992 E-mail: ivyeditingmb@gmail.com Website: www.ivy-editing.com. www.ivy-editing.com. 论文核心内容 1 )标题 2 )摘要 3 )正文. E-mail: ivyeditingmb@gmail.com ; Tel: 021 - 51370992.

Download Presentation

最大限度地展示您的研究成果 英语医学论文写作实例分析 张科宏博士 常青藤编辑总裁 同济大学兼职教授 哈佛大学医学院助理教授( 2003 - 2007 ) Tel: 021-51370992

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. www.ivy-editing.com 最大限度地展示您的研究成果 英语医学论文写作实例分析 张科宏博士 常青藤编辑总裁 同济大学兼职教授 哈佛大学医学院助理教授(2003-2007) Tel: 021-51370992 E-mail: ivyeditingmb@gmail.com Website: www.ivy-editing.com

  2. www.ivy-editing.com 论文核心内容 1)标题 2)摘要 3)正文 E-mail: ivyeditingmb@gmail.com; Tel: 021-51370992

  3. www.ivy-editing.com 论文核心内容 1)标题 目的:在第一时刻抓住读者/审稿人的目光 E-mail: ivyeditingmb@gmail.com; Tel: 021-51370992

  4. www.ivy-editing.com 论文核心内容 1)标题 目的:在第一时刻抓住读者/审稿人的目光 技巧:把主要研究结果 “装入” 标题 E-mail: ivyeditingmb@gmail.com; Tel: 021-51370992

  5. www.ivy-editing.com 论文核心内容 1)标题 2)摘要 目的:吸引读者/审稿人引入正文 E-mail: ivyeditingmb@gmail.com; Tel: 021-51370992

  6. www.ivy-editing.com 论文核心内容 1)标题 2)摘要 目的:吸引读者/审稿人引入正文 技巧:给出一个基本独立的“故事梗概” E-mail: ivyeditingmb@gmail.com; Tel: 021-51370992

  7. www.ivy-editing.com 论文核心内容 1)标题 2)摘要 3)正文 目的:将一个完整的 “故事” 呈现给读者 E-mail: ivyeditingmb@gmail.com; Tel: 021-51370992

  8. www.ivy-editing.com 论文核心内容 1)标题 2)摘要 3)正文 目的:将一个完整的 “故事” 呈现给读者 技巧:换位思维,撰写稿件时以读者为中心 E-mail: ivyeditingmb@gmail.com; Tel: 021-51370992

  9. www.ivy-editing.com Effects of nifedipine on blood pressure in patients with primary hypertension vs. healthy controls E-mail: ivyeditingmb@gmail.com; Tel: 021-51370992

  10. www.ivy-editing.com Effects of nifedipine on blood pressure in patients with primary hypertension vs. healthy controls Nifedipine decreases blood pressure in patients with primary hypertension but not in healthy controls E-mail: ivyeditingmb@gmail.com; Tel: 021-51370992

  11. www.ivy-editing.com Abstract The present study examined the role of dopamine D4 receptor on prepulse inhibition in rats. Gating deficit was induced pharmacologically using ketamine. Rats then received daily treatment with the D4-selective antagonist CP-293,019 vs. saline. ….. E-mail: ivyeditingmb@gmail.com; Tel: 021-51370992

  12. www.ivy-editing.com Abstract Abberant information processing (e.g., gating deficit) is the basis of many cognitive deficits in schizophrenia. Since dopamine D4 receptor is elevated in the brain of schizophrenia patients, we examined whether D4 receptor antagonism could alleviate gating deficit in a rat model. Prepulse inhibition was disrupted ……. E-mail: ivyeditingmb@gmail.com; Tel: 021-51370992

  13. E-mail: ivyeditingmb@gmail.com International Journal of Radiation Oncology Biology Physics, 67:888-896, 2007 Due to the complex molecular pathogenesis of glioblastoma multiforme, therapeutic strategies are evolving from cytotoxic therapies to molecular approaches which target specific signaling cascades that promote tumor growth such as cyclooxygenase-2 (COX-2), a rate-limiting enzyme in conversion of arachidonic acid into prostaglandins. Tel: 021-51370992 www.ivy-editing.com

  14. E-mail: ivyeditingmb@gmail.com International Journal of Radiation Oncology Biology Physics, 67:888-896, 2007 Due to the complex molecular pathogenesis of glioblastoma multiforme, therapeutic strategies are evolving from cytotoxic therapies to molecular approaches which target specific signaling cascades that promote tumor growth such as cyclooxygenase-2 (COX-2), a rate-limiting enzyme in conversion of arachidonic acid into prostaglandins. Tel: 021-51370992 www.ivy-editing.com

  15. E-mail: ivyeditingmb@gmail.com International Journal of Radiation Oncology Biology Physics, 67:888-896, 2007 Due to the complex molecular pathogenesis of glioblastoma multiforme, therapeutic strategies are evolving from cytotoxic therapies to molecular approaches which target specific signaling cascades that promote tumor growth such as cyclooxygenase-2 (COX-2), a rate-limiting enzyme in conversion of arachidonic acid into prostaglandins. Tel: 021-51370992 www.ivy-editing.com

  16. E-mail: ivyeditingmb@gmail.com International Journal of Radiation Oncology Biology Physics, 67:888-896, 2007 Due to the complex molecular pathogenesis of glioblastoma multiforme, therapeutic strategies are evolving from cytotoxic therapies to molecular approaches which target specific signaling cascades that promote tumor growth such as cyclooxygenase-2 (COX-2), a rate-limiting enzyme in conversion of arachidonic acid into prostaglandins. Tel: 021-51370992 www.ivy-editing.com

  17. E-mail: ivyeditingmb@gmail.com International Journal of Radiation Oncology Biology Physics, 67:888-896, 2007 Due to the complex molecular pathogenesis of glioblastoma multiforme, therapeutic strategies are evolving from cytotoxic therapies to molecular approaches which target specific signaling cascades that promote tumor growth such as cyclooxygenase-2 (COX-2), a rate-limiting enzyme in conversion of arachidonic acid into prostaglandins. Tel: 021-51370992 www.ivy-editing.com

  18. E-mail: ivyeditingmb@gmail.com International Journal of Radiation Oncology Biology Physics, 67:888-896, 2007 Due to the complex molecular pathogenesis of glioblastoma multiforme, therapeutic strategies are evolving from cytotoxic therapies to molecular approaches which target specific signaling cascades that promote tumor growth such as cyclooxygenase-2 (COX-2), a rate-limiting enzyme in conversion of arachidonic acid into prostaglandins. Tel: 021-51370992 www.ivy-editing.com

  19. E-mail: ivyeditingmb@gmail.com Due to the complex molecular pathogenesis of glioblastoma multiforme, therapeutic strategies are evolving from cytotoxic therapies to molecular approaches which target specific signaling cascades that promote tumor growth such as cyclooxygenase-2 (COX-2), a rate-limiting enzyme in conversion of arachidonic acid into prostaglandins. Despite of the complex molecular pathogenesis of glioblastoma multiforme, therapeutic strategies are evolving from cytotoxic therapies to molecular approaches. Tel: 021-51370992 www.ivy-editing.com

  20. E-mail: ivyeditingmb@gmail.com Due to the complex molecular pathogenesis of glioblastoma multiforme, therapeutic strategies are evolving from cytotoxic therapies to molecular approaches which target specific signaling cascades that promote tumor growth such as cyclooxygenase-2 (COX-2), a rate-limiting enzyme in conversion of arachidonic acid into prostaglandins. Despite of the complex molecular pathogenesis of glioblastoma multiforme, therapeutic strategies are evolving from cytotoxic therapies to molecular approaches. Activation of cyclooxygenase-2 (COX-2), the rate-limiting enzyme in prostaglandinbiosynthesis, promotes tumor growth, and therefore represents a promising target for intervention. Tel: 021-51370992 www.ivy-editing.com

  21. E-mail: ivyeditingmb@gmail.com Results In order to examine the effects of sitagliptin on glucose level, diabetic rats were treated with various doses of sitagliptin. The blood glucose level was significantly different between the H and M groups compared with the C group. However, the L group was not statistically different from the C group. Tel: 021-51370992 www.ivy-editing.com

  22. E-mail: ivyeditingmb@gmail.com Results In order to examine the effects of sitagliptin on glucose level, diabetic rats were treated with various doses of sitagliptin. The blood glucose level was significantly different between the H and M groups compared with the C group. However, the L group was not statistically different from the C group. Tel: 021-51370992 www.ivy-editing.com

  23. E-mail: ivyeditingmb@gmail.com Results In order to examine the effects of sitagliptin on glucose level, diabetic rats were treated with various doses of sitagliptin. The blood glucose level was significantly different between the H and M groups compared with the C group. However, the L group was not statistically different from the C group. Tel: 021-51370992 www.ivy-editing.com

  24. E-mail: ivyeditingmb@gmail.com Results In order to examine the effects of sitagliptin on glucose level, diabetic rats were treated with various doses of sitagliptin. The blood glucose level was significantly different between the H and M groups compared with the C group. However, the L group was not statistically different from the C group. Tel: 021-51370992 www.ivy-editing.com

  25. E-mail: ivyeditingmb@gmail.com Results In order to examine the effects of sitagliptin on glucose level, diabetic rats were treated with various doses of sitagliptin. The blood glucose level was significantly different between the H and M groups compared with the C group. However, the L group was not statistically different from the C group. Tel: 021-51370992 www.ivy-editing.com

  26. E-mail: ivyeditingmb@gmail.com Results In order to examine the effects of sitagliptin on glucose level, diabetic rats were treated with various doses of sitagliptin. The blood glucose level was significantly different between the H and M groups compared with the C group. However, the L group was not statistically different from the C group. Results Sitagliptin significantly decreased blood glucose concentration in diabetic rats at 150 and 75 mg/kg/d, but not at a lower dose of 37.5 mg/kg/d. Tel: 021-51370992 www.ivy-editing.com

  27. E-mail: ivyeditingmb@gmail.com Lung cancer is one of the most frequent human cancers and the leading cause of cancer-related deaths in both men and women in the United States and around the world. Non-small cell lung carcinoma (NSCLC) constitutes approximately 80% of all primary lung cancers with a 5-year relative survival of 15%. Prognostic factors usually were helpful in the clinic management and response evaluation for therapy in lung cancer, which could identify subsets of patients with worse prognosis who might benefit from a more aggressive treatment strategy. For example, the TNM staging system is clinically used to guide treatment decisions and predict prognosis for patients with NSCLC. Poor differentiation, vascular invasion, and inadequate lymph node dissection have been suggested as factors to be considered for deciding on the need or the extent of adjuvant therapy in stage I-II NSCLC. However, the fact that disease relapse rates are as high as 30%, even among stage IA patients, has led to an interest in identifying additional prognostic factors for NSCLC. Tel: 021-51370992 www.ivy-editing.com

  28. E-mail: ivyeditingmb@gmail.com Lung cancer is one of the most frequent human cancers and the leading cause of cancer-related deaths in both men and women in the United States and around the world. Non-small cell lung carcinoma (NSCLC) constitutes approximately 80% of all primary lung cancers with a 5-year relative survival of 15%. Prognostic factors usually were helpful in the clinic management and response evaluation for therapy in lung cancer, which could identify subsets of patients with worse prognosis who might benefit from a more aggressive treatment strategy. For example, the TNM staging system is clinically used to guide treatment decisions and predict prognosis for patients with NSCLC. Poor differentiation, vascular invasion, and inadequate lymph node dissection have been suggested as factors to be considered for deciding on the need or the extent of adjuvant therapy in stage I-II NSCLC. However, the fact that disease relapse rates are as high as 30%, even among stage IA patients, has led to an interest in identifying additional prognostic factors for NSCLC. 内容:细胞吸附因子-预后 目标杂志:Lung Cancer Tel: 021-51370992 www.ivy-editing.com

  29. E-mail: ivyeditingmb@gmail.com Lung cancer is one of the most frequent human cancers and the leading cause of cancer-related deaths in both men and women in the United States and around the world. Tel: 021-51370992 www.ivy-editing.com

  30. E-mail: ivyeditingmb@gmail.com Lung cancer is one of the most frequent human cancers and the leading cause of cancer-related deaths in both men and women in the United States and around the world. Tel: 021-51370992 www.ivy-editing.com

  31. E-mail: ivyeditingmb@gmail.com Lung cancer is one of the most frequent human cancers and the leading cause of cancer-related deaths in both men and women in the United States and around the world. Tel: 021-51370992 www.ivy-editing.com

  32. E-mail: ivyeditingmb@gmail.com Non-small cell lung carcinoma (NSCLC) constitutes approximately 80% of all primary lung cancers with a 5-year relative survival of 15%. Tel: 021-51370992 www.ivy-editing.com

  33. E-mail: ivyeditingmb@gmail.com Non-small cell lung carcinoma (NSCLC) constitutes approximately 80% of all primary lung cancers with a 5-year relative survival of 15%. Tel: 021-51370992 www.ivy-editing.com

  34. E-mail: ivyeditingmb@gmail.com Prognostic factors usually were helpful in the clinic management and response evaluation for therapy in lung cancer, which could identify subsets of patients with worse prognosis who might benefit from a more aggressive treatment strategy. Tel: 021-51370992 www.ivy-editing.com

  35. E-mail: ivyeditingmb@gmail.com Prognostic factors usually were helpful in the clinic management and response evaluation for therapy in lung cancer, which could identify subsets of patients with worse prognosis who might benefit from a more aggressive treatment strategy. Tel: 021-51370992 www.ivy-editing.com

  36. E-mail: ivyeditingmb@gmail.com Prognostic factors usually were helpful in the clinic management and response evaluation for therapy in lung cancer, which could identify subsets of patients with worse prognosis who might benefit from a more aggressive treatment strategy. Tel: 021-51370992 www.ivy-editing.com

  37. E-mail: ivyeditingmb@gmail.com Prognostic factors usually were helpful in the clinic management and response evaluation for therapy in lung cancer, which could identify subsets of patients with worse prognosis who might benefit from a more aggressive treatment strategy. Tel: 021-51370992 www.ivy-editing.com

  38. E-mail: ivyeditingmb@gmail.com For example, the TNM staging system is clinically used to guide treatment decisions and predict prognosis for patients with NSCLC. Tel: 021-51370992 www.ivy-editing.com

  39. E-mail: ivyeditingmb@gmail.com For example, the TNM staging system is clinically used to guide treatment decisions and predict prognosis for patients with NSCLC. Tel: 021-51370992 www.ivy-editing.com

  40. E-mail: ivyeditingmb@gmail.com Prognostic factors usually were helpful in the clinic management and response evaluation for therapy in lung cancer, which could identify subsets of patients with worse prognosis who might benefit from a more aggressive treatment strategy. For example, the TNM staging system is clinically used to guide treatment decisions and predict prognosis for patients with NSCLC. Tel: 021-51370992 www.ivy-editing.com

  41. E-mail: ivyeditingmb@gmail.com Poor differentiation, vascular invasion, inadequate lymph node dissection and extracapsular spread have been suggested as factors to be considered for deciding on the need or the extent of adjuvant therapy in stage I-II NSCLC. Tel: 021-51370992 www.ivy-editing.com

  42. E-mail: ivyeditingmb@gmail.com Poor differentiation, vascular invasion, and inadequate lymph node dissection have been suggested as factors to be considered for deciding on the need or the extent of adjuvant therapy in stage I-II NSCLC. Tel: 021-51370992 www.ivy-editing.com

  43. E-mail: ivyeditingmb@gmail.com However, the fact that disease relapse rates are as high as 30%, even among stage IA patients, has led to an interest in identifying additional prognostic factors for NSCLC. Tel: 021-51370992 www.ivy-editing.com

  44. E-mail: ivyeditingmb@gmail.com However, the fact that disease relapse rates are as high as 30%, even among stage IA patients, has led to an interest in identifying additional prognostic factors for NSCLC. Tel: 021-51370992 www.ivy-editing.com

  45. E-mail: ivyeditingmb@gmail.com However, the fact that disease relapse rates are as high as 30%, even among stage IA patients, has led to an interest in identifying additional prognostic factors for NSCLC. Tel: 021-51370992 www.ivy-editing.com

  46. E-mail: ivyeditingmb@gmail.com Non-small cell lung carcinoma (NSCLC) constitutes approximately 80% of all primary lung cancers, and has relatively poor prognosis. Prognostic factors, whether included in the TNM system or not, are helpful in predicting long-term survival, and to guide treatment decisions. For example, poorly differentiated tumors, vascular invasion, inadequate removal of the lymph nodes and extracapsular spread have been associated with the need for more aggressive adjuvant therapy. Tel: 021-51370992 www.ivy-editing.com

  47. E-mail: ivyeditingmb@gmail.com Non-small cell lung carcinoma (NSCLC) constitutes approximately 80% of all primary lung cancers, and has relatively poor prognosis. Prognostic factors, whether included in the TNM system or not, are helpful in predicting long-term survival, and to guide treatment decisions. For example, poorly differentiated tumors, vascular invasion, and inadequate removal of the lymph nodes have been associated with the need for more aggressive adjuvant therapy. The core features of cancer (e.g., uncontrolled growth, invasion, and metastais) are influenced by the expression of cell adhesion molecules. ……… Tel: 021-51370992 www.ivy-editing.com

  48. E-mail: ivyeditingmb@gmail.com 1)文字表述 2)科学逻辑 3)概念层次/思路组织 Tel: 021-51370992 www.ivy-editing.com

  49. 丁香园论文版,www.dxy.cn

  50. 丁香园论文版,www.dxy.cn

More Related